Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity

Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its high valuation and slowing growth. The combination has weighed on price action since early 2025 and is unlikely to go away soon. However, the high valuation today prices in a solid growth outlook, ultimately undervaluing the company’s potential.

Intuitive Surgical’s potential is the dominance of robotic surgical procedures. The company has a first-mover advantage, with an installed base of over 12,000 devices and growing. In this scenario, the 45X valuation relative to current year earnings is only a small hurdle, given the potential for a 50% or greater stock price increase over the next few years.

And that is assuming the long-term forecasts are accurate. As it stands, Intuitive Surgical consistently outperforms its expectations and device deployments and procedure volumes continue to grow.

The more likely scenario is that ISRG continues to outperform and drives a bullish revision cycle over the long-term.

Market Overreaction Sets Up ISRG Opportunity

Analysts played a role in ISRG’s stock price decline in 2026. The trend leading up to the fiscal Q1 2026 release was downward price target revisions, but the market overreacted, creating a deep value opportunity. The revision trend affirms the consensus price target, which forecasts more than 30% upside from critical support levels, and there is a high conviction in the forecast. MarketBeat tracks 25 analysts, rating the stock a consensus Moderate Buy, with a 68% Buy-side bias echoed in the institutional activity.

The institutional activity is telling. The group owns more than 80% of the stock and has been accumulating throughout the corrective period. Their activity ramped into Q1 2026 and remained strong in the first weeks of Q2. The trailing 12-month balance is nearly $2-to-$1 in favor of buyers, with Q1 and Q2 activity reflecting accelerating demand. The takeaway is that ISRG has a solid floor in the $445 to $450 region and is set up for a robust rebound in Q2 and the latter part of 2026.

Stock price action reflects the institutional activity, with trading declines halted near $445 and rebounds ensuing. The setup in mid-Q2 is for a rebound, with the market showing support at the critical level and advancing following the Q1 release. Indicators such as MACD and stochastic are also aligned, suggesting a trend-following move that could take this market back to record levels. The technical hurdles include the long-term 150-day exponential moving average near $500 and resistance targets at previous price peaks near $560 and $600.

Buybacks Add Leverage: Underpin Stock Price Outlook

Buybacks are among the reasons this stock can set new highs. Not only is the company outperforming and forward estimates improving, but buybacks have improved shareholder leverage. The Q1 release reveals more than $1.1 billion in quarterly repurchases, enough to reduce the count by 0.15% sequentially and approximately 1.3% compared to the prior year’s period, and the capacity to continue buying shares at a robust pace.

Intuitive Surgical’s balance sheet shows the impacts of buybacks and acquisitions, but they are offset by cash flow strength and the shareholder leverage gained. Critical details include reduced cash, offset by reduced liabilities and relatively steady equity. In this scenario, ISRG can continue to buy back shares while maintaining balance sheet health indefinitely, including a zero-debt balance. As it stands, Intuitive Surgical’s balance sheet is net cash relative to total liabilities, with cash more than 3.15X liabilities, potentially the strongest balance sheet on Wall Street.

Intuitive Surgical’s Q1 Release Triggers Market Rebound

Intuitive Surgical had a robust Q1, affirming its trends and the probability that the forward estimates are far off. The $2.77 billion in net revenue is up 23.1% year over year, outpacing the consensus by more than 550 basis points (bps). Growth was driven by device placement (up 17%), procedure volume (up 17%), and Instrument sales (up 23%). The installed base grew by 12%, pointing to continued gains in upcoming quarters, and the margin improved.

The company’s adjusted net income grew by 36%, outpacing the topline by more than 1300 bps, and is expected to remain strong in the upcoming quarters. Guidance is for full-year Da Vinci device growth of approximately 14.5%, with procedures and instruments sales following suit.

The biggest risk for this company, other than valuation, is competition, but it is trailing significantly. The closest is Medtronic’s (NYSE: MDT) Hugo device, which has seen success in overseas markets but is still in its early rollout stages. Catalysts for ISRG include the early success of Da Vinci 5, the AI opportunity and expansion into international markets. Japan, specifically, recently approved seven new robotic procedures and is seen as a significant driver of growth.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

The article "Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity" first appeared on MarketBeat.